


Supplementary Figure 9



Supplementary Figure S9. Single cell clones of the Rael-BL human Burkitt lymphoma cell line with complete removal of mutant TP53 expression do not display impaired survival or proliferation

A. Western blot analysis showing the complete absence of mutant TP53 in single cell clones of Rael-BL lymphoma cells that had been transduced with Cas9 and a TP53 specific sgRNA and treated with doxycycline (*isgTP53*). Cloned Rael-BL lymphoma cells that had been transduced with Cas9 and a non-targeting control sgRNA (*isgNC*) and treated with doxycycline were used as a control. Probing for β -ACTIN was used as a protein loading control. The Western blots shown are representative of 2 or 3 independent blots from independent experiments. **B.** In vitro growth the lymphoma cells described in (A) grown in medium with 1% FCS, 3% FCS or 10% FCS. **C.** In vitro survival of the cells described in (A, B) was determined by flow cytometric analysis. **D.** Cell cycle analysis of the lymphoma cells described in (A, B). **E.** Mitotracker staining of the cells described in (A, B). **F.** CellROX staining of the cells described in (A, B). **G.** Survival of control mutant TP53 expressing Rael-BL lymphoma cells and the mutant TP53 deleted derivatives after treatment in culture with the indicated concentrations of etoposide or vehicle. Data in (B), (C) and (G) are presented as mean \pm SEM of experiments conducted in triplicate. Data presented in (D), (E) and (F) are representative of at least 3 independent experiments. There were no consistent significant differences between the mutant TP53 deleted Rael-BL lymphoma cells vs the control lymphoma cells in any of the experiments.